Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2023-02-16 AGM Information
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Chairman's address 2 pages 153.0KB
AGM Information Classification · 95% confidence The document is an ASX announcement dated 17 February 2023, containing the Chairman's address to an Extraordinary General Meeting (EGM). It discusses company progress, clinical trial plans, capital raising, and resolutions to be voted on at the meeting. The content is focused on providing background and context for the EGM resolutions rather than presenting financial results or detailed reports. The document is relatively short (4638 characters) and serves as meeting-related information rather than a full report or financial statement. Therefore, it fits best as AGM Information (AGM-R), which includes presentations and materials shared during general meetings, including EGMs and AGMs.
2023-02-16 English
EGM Presentation 22 pages 2.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation dated 17th February 2023, focused on InhaleRx Limited's business overview, clinical programs, management team, drug development plans, and upcoming milestones. It includes forward-looking statements, clinical trial phases, regulatory pathways (FDA 505(b)(2)), and strategic information aimed at investors or stakeholders. The content is structured as a presentation with slides, disclaimers, and executive summaries, typical of investor presentations. There is no indication that this is an official annual report, earnings release, or regulatory filing. The document is not a transcript of a call, nor a voting result or legal proceeding. It is clearly a detailed investor presentation outlining company strategy, pipeline, and market opportunity.
2023-02-16 English
Results of Meeting 2 pages 143.4KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Results of Extraordinary General Meeting' and details the voting outcomes on various resolutions passed at the EGM held on 17 February 2023. It includes proxy vote counts, percentages for and against, and abstentions for each resolution. There is no financial data, management discussion, or report attached; rather, it is an announcement of the voting results from a shareholder meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is short (2805 characters), consistent with an announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2023-02-16 English
Notification regarding unquoted securities - IRX 10 pages 39.0KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed notification regarding the issue of unquoted equity securities, specifically options issued under an employee incentive scheme. It includes information about the number and type of securities issued, dates, exercise prices, and details about key management personnel receiving these securities. The document is structured as a formal announcement to the ASX (Australian Securities Exchange) about securities issuance, not a financial report or earnings release. It does not contain financial statements or management discussion of financial results. This type of filing corresponds to announcements about share issues or capital changes, specifically the issuance of new securities. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive notification of securities issuance.
2023-02-12 English
Quarterly Appendix 4C Cash Flow Report 5 pages 189.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements for the quarter ended 31 December 2022. It includes consolidated statements of cash flows from operating, investing, and financing activities, reconciliation of cash and cash equivalents, payments to related parties, financing facilities, and estimated cash available for future operating activities. The document is over 10,000 characters, indicating it is a full report rather than a brief announcement. The content aligns with a comprehensive interim or quarterly financial report containing substantive financial data and analysis. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2022
2023-01-30 English
Quarterly Activities Report 5 pages 552.5KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 31 January 2023, titled 'Quarterly Activities, Cashflow Report and Operations Update' for the quarter ended 31 December 2022. It contains detailed operational highlights, cash flow figures, clinical trial updates, regulatory interactions, and use of funds for the quarter. The presence of actual financial data such as cash reserves, net cash used in operating activities, and detailed expenditure indicates this is a comprehensive quarterly financial and operational report. It is not merely an announcement of a report or a certification. The document length (10,374 characters) supports it being a substantive report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q4 2022
2023-01-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.